[Effects of thymectomy and glucocorticoid therapy on peripheral lymphocytes in myasthenia gravis] NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Effects of thymectomy and glucocorticoid therapy on peripheral lymphocytes in myasthenia gravis]

Chung Hua Nei Ko Tsa Chih. 1995 Aug;34(8):514-7. Unique Identifier : AIDSLINE MED/96329747
Huang Y; Xu X; Lin J; Peking Union Medical College Hospital, Beijing.

Abstract: Clinical manifestations and peripheral blood lymphocyte subset changes were studied in patients with myasthenia gravis (MG) to elucidate the mechanism of clinical improvement following treatment, with thymectomy (Tx) or glucocorticoid (GC) therapy. The changes found were: 1. There was a significant increase in percentages of CD3+, CD29+ CD4+ cells and CD4/CD8 ratio and a significant decrease in percentages of CD8+ and CD16,56+ cells in patients who had never been treated with any immune therapy. 2. After Tx or GC therapy, CD3+ and CD4+, CD29+ cells were decreased, but the number CD19+ and CD16, CD56 cells did not change. 3. Tx had a special effect on CD8+ cells. In most of the patients who showed clinical improvement after Tx, CD8+ cells were increased and CD4/CD8 ratio wad decreased. 4. Anti-acetylcholine receptor (AChRAb) titers were markedly decreased after GC therapy. These results indicate that there were obvious abnormalities in cell-mediated immunity in addition to those in humoral immunity in myasthenia gravis. These abnormalities tended to be normalized after Tx or GC therapy.
Keywords: Adolescence Adult Autoantibodies/BLOOD Child Comparative Study CD4-CD8 Ratio English Abstract Female Human Male Middle Age Myasthenia Gravis/DRUG THERAPY/*IMMUNOLOGY/SURGERY Prednisone/*THERAPEUTIC USE Receptors, Cholinergic/IMMUNOLOGY Support, Non-U.S. Gov't T-Lymphocyte Subsets/*IMMUNOLOGY *Thymectomy JOURNAL ARTICLEKWDadolescenceadultautoantibodies/bloodchildcomparativestudycd4-cd8ratioenglishabstractfemalehumanmalemiddleagemyastheniagravis/drugtherapy/KWDimmunology/surgeryprednisone/KWDtherapeuticusereceptors,cholinergic/immunologysupport,non-uKWDsKWDgov'tt-lymphocytesubsets/KWDimmunologyKWDthymectomyjournalarticle
961130
M96B1836

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .